Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2014
February 04, 2014
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Yutaro Shintaku, President and Representative Director: Masayuki Maruta, General Manager, Corporate Communication Dept.
: +81 / 3-6742-8550

Company code number
Representative:
Please address all communications toPhone

1. Consolidated financial highlights for the interim period ended December 2013
(From April 1, 2013 to December 31, 2013)(Note: The amounts shown below ignore values of less than a million yen)

Net sales

Operating income(Millions of yen)

Nine months ended December, 2013
Nine months ended December, 2012
(Notes) 1. Comprehensive income:%

345,260
295,749(Millions of yen)%

48,251
42,62816.7
2.4

Ordinary income

December 2013: 83,517million yen (104.4%)(Millions of yen)

49,91940,45313.2(14.5)

Net income%(Millions of yen)

36,896
24,707

23.4(12.7)

%

49.3
12.5

December 2012: 40,856million yen (−%)

2. Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.
Net income per share,
fully diluted

Net income per share(Yen)

Nine months ended December, 2013
Nine months ended December, 2012

(Yen)

194.32130.12

194.31−(2) Consolidated financial position(Note: The amounts shown below ignore values of less than a million yen)

Total assets

As at December 31, 2013
As at March 31, 2013

Net assets per share

Equity ratio

Net assets(Millions of yen)

(Millions of yen)%(Yen)

863,324
771,032

511,406
437,90959.2
56.7

2,693.32
2,304.42(Note) Shareholders' equity : December 31, 2013: 511,394 million yen, March 31, 2013: 437,557 million yen.

2. Dividends
Cash dividends per share
4th quarter

1st quarter 2nd quarter 3rd quarter

Year ended March 31, 2013
Year ending March 31, 2014
Year ending March 31, 2014 (forecast)

total(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

−
−

22.00
29.00

−
−

22.00

44.00

29.00

58.00

(Note) Revise of dividends forecast : None

3. Consolidated forecast for the year ending March 2014 (From April 1, 2013 to March 31, 2014)
Net salesYear ending March, 2014Ordinary income

Operating income

Net income
per share

Net income(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

460,000

14.3

70,00031.5

67,50031.4

42,000(10.7)(Yen)

221.201. Forecast for fiscal year ending March, 2014 which was announced on May 9, 2013 has not been revised.
(Assumed exchange rate for the fiscal year ending March, 2014: USD1=JPY100, EUR1=JPY134)
2. Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these areforecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results
may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economicconditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

14. Consolidated Financial Statements(1) Consolidated Balance Sheets(Millions of yen)

(Assets)
I Current assets

As at March 31, 2013

As at December 31,2013

AmountAmount286,955%37.2%

319,205

Cash and deposits

78,201

94,866

Notes and accounts receivable−trade

95,008

108,575

Inverntories

85,17996,248Deferred tax assets

11,258

10,384

Other

18,528

10,522

Allowance for doubtful accounts(1,220)(1,391)%
37.0%

II Noncurrent assets

483,77062.8%

543,11662.9%

1. Property, plant and equipment

144,82418.8%

167,978

19.5%

Buildings and structures

48,96653,066

Machinery, equipment and vehicles

46,366

51,538Land

21,827

21,785704

521

17,79431,070

Lease assets
Construction in progress
Other

9,1659,996

2. Intangible assets

296,634

Goodwill

149,322160,343

Customer relationships

90,706

97,404Other

56,60464,612

3. Investments and other assets

42,311

38.5%

5.5%

322,360

52,778Investment securities

30,304

37,130

Deferred tax assets

5,153

3,266

Other

6,852

12,380

III Deferred assets
Total assets

2

37.3%

6.1%

306

0.0%

1,001

0.1%

771,032

100.0%

863,324100.0%

(Millions of yen)

(Liabilities)
I Current liabilities

As at March 31, 2013

As at December 31,2013

AmountAmount%115,844

15.0%%

126,071Notes and accounts payable−trade37,51536,922

Short−term loans payable

18,046

10,500Current portion of long−term loans payable

3,762

4,460

277

205

2,609

14,637

Lease obligations
Income taxes payable
Deferred tax liabilities

3583

Provision for bonuses

4,834

2,508

109

81

6,624

12,533

420−41,611

44,137

Provision for directors' bonuses
Notes and accounts payable − facilities
Asset retirement obligations
Other

II Noncurrent liabilities

217,27828.2%

225,846

Bonds payable

80,00080,000Long−term loans payable

78,71282,160439

308

Deferred tax liabilities

49,65954,072

Provision for retirement benefits

1,247
198

1,567
66

155

157

6,865

7,514

Lease obligations

Provision for directors' retirement benefits
Asset retirement obligations
Other

Total liabilities(Net assets)
I Shareholders' equity

43.2%

351,91740.8%

419,99954.5%

447,200

51.8%

38,716

38,716

Capital surplus

52,103

52,103Retained earnings

329,188356,400

Treasury stock(9)17,557

Valuation difference on available−for−sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment

III Subscription rights to shares
IV Minority interests
Total net assets
Total liabilities and net assets

326.2%

333,122

Capital stock

II Accumulated other comprehensive income

14.6%

(20)
2.3%

7,458

64,1947.4%

11,909−(16)

10,09952,302−−110.0%

352

0.0%

−−

437,90956.8%

511,406

59.2%

771,032

100.0%

863,324100.0%

(2) Consolidated Statements of Income(Millions of yen)

For nine months ended
December 31, 2012
AmountI Net sales
II Cost of sales
Gross profit
III Selling, general and administrative expenses
Operating income
IV Non-operating income%

For nine months ended
December 31, 2013
Amount%295,749

100.0%

345,260

100.0%

142,26148.1%

166,599

48.3%

153,487
110,859

51.9%
37.5%

178,661
130,409

51.7%
37.7%

42,628

14.4%

48,251

14.0%

6,131

1.8%

Interest income

221

287

Dividends income

191

226

Royalty income8781

Foreign exchange gains

15

4,664

Equity in earnings of affiliates

134

96

Other

575

1,225

0.4%

776

V Non-operating expenses
Interest expenses

948

1,124

Sales discounts

447

479

Loss on disposal of inventories

560

75

Other

1,443

Ordinary income
VI Extraordinary income

3,399

1.1%

40,453

13.7%

2,784

Gain on sales of noncurrent assets

477

Gain on transfer of businessSubsidy income

−
875

299
−

Settlement received

−

922

0.3%

6,000

4,464

1.3%

49,919

14.5%

6,307

1.8%

VII Extraordinary expenses
Loss on disposal of noncurrent assets

451

216

Impairment loss−

561

Directors' retirement benefits−

33

Loss on liquidation of business−

881

Loss on valuation of golf club memberships

3−

Environmental expenses

390

Income before income taxes
Income taxes-current

17,564

Income taxes-deferred(1,773)

Income before minority interests
Minority interests in income

Net income

4845

0.3%

40,530

13.7%

−

1,693

0.5%

54,53315.8%

18,041
15,7905.3%

17,606

5.1%

24,739
32

8.4%
0.0%

(434)

36,926
30

10.7%
0.0%

24,707

8.4%

36,896

10.7%

(3) Consolidated statement of comprehensive income(Millions of yen)

For nine months ended
December 31, 2012

For nine months ended
December 31, 2013

AmountAmount

I Income before minority interests
II Othercomprehensive
incomeValuationdifference on
available-for-salesecurities

24,73936,926

Valuation difference on available-for-sale securities

1,678

4,450

Deferred gains or losses on hedges
Foreign currency translation adjustments
Share of other comprehensive income of associates
accounted for using equity method(38)
14,476(16)
42,1581

Comprehensive income

16,116(2)

46,59040,856

83,51740,826

83,53029(13)

Attributable to:Shareholders of Terumo Corporation
Minority interests

55. Segment Information[Reportable Segments](1) The Third Quarter of Fiscal Year Ended March 31, 2013
For nine months ended
December 31, 2012
GeneralHospitalBusiness

Cardiac &VascularBusiness

Blood
Management
Business(Millions of yen)

Subtotal

Adjustment

Total

Sales and operating income:Sales to customer

119,791

122,305

53,652295,749−−−−−−−

Sales total

119,791

122,305

53,652295,749−

295,749

Segment income (loss)

18,651
19,5301,880
40,061
2,566
42,628
1. The 2,566 million yen adjustment to segment profit is the sum of the 570

Internal sales

Notes:

295,749

million yen for inventories and the 1,995 million yen for others.
2. Segment profit is adjusted to be consistent with operating income shown on thequarterly consolidated income statement.
(2) The Third Quarter of Fiscal Year Ending March 31, 2014
For nine months ended
December 31, 2013
GeneralHospitalBusiness

Cardiac &VascularBusiness

Blood
Management
Business(Millions of yen)

Subtotal

Adjustment

Total

Sales and operating income:Sales to customer

123,910

153,873

67,476345,260−−−−−−−

Sales total

123,910

153,873

67,476345,260−

345,260

Segment income (loss)

16,21830,081
3,042
49,342(1,090)48,251
1. The (1,090) million yen adjustment to segment profit is the sum of the (626)Internal sales

Notes:

345,260

million yen for inventories and the (464) million yen for others.
2. Segment profit is adjusted to be consistent with operating income shown on thequarterly consolidated income statement.

(Note) Main products belonging to each business segment
Business segments

Main products

General Hospital business
Disposable medical devices and medical electronics

Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters,
Infusion pumps, Syringe pumps, etc.

Pharmaceuticals

I.V.solutions, Nutritious food, Prefilled syringes, CAPD systems, etc.

Diabetes care products

Blood glucose monitoring systems

Consumer Healthcare business

Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.

Cardiac and Vascular business
Interventional systems

Angiographic catheters, PTCA balloon catheters, Coronary stents, Neuro interventionalcoils, etc.

Cardiovascular systems

Oxygenerators, Cardio-pulmonary bypass system, Left ventricular assist system, etc.

Vascular grafts

Artificial vascular grafts, Stent grafts

Blood Management business

Blood bags, Automated blood collection system, Therapeutic apheresis system, Cell
expansion system, etc.

6